▷ Adaptate Biotherapeutics Ltd, London
Takeda en passe d'acquérir Adaptate Biotherapeutics pour développer de nouvelles thérapies associées aux engageurs de cellules T Gamma Delta (γδ) ciblant les tumeurs solides | Business Wire
Takeda to acquire Adaptate for novel T-cell engager technology
GammaDelta spins out new company Adaptate Biotherapeutics
Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells - Pharma Journalist
Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells | Business Wire
Adaptate Biotherapeutics Company Profile: Valuation, Investors, Acquisition | PitchBook
Zyme Communications on X: "Adaptate Biotherapeutics today announced the appointment of Stewart Kay as Chief Business Officer to drive the Company's #Business and #Corporate Development activities. Read the full announcement here: https://t.co/nMwYvBokyi
Oncologie : Takeda va acquérir Adaptate Biotherapeutics
Milestone: White City Place W12
IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets
Takeda adquirirá Adaptate Biotherapeutics - enFarma
Adaptate Biotherapeutics Raises $18 million in Series A2 Funding | Technology Networks
Dr Mihriban Tuna appointed Chief Scientific Officer at new biotechnology start-up - News & insight - Cambridge Judge Business School
Natalie Mount - Non-Executive Director at Rinri Therapeutics | The Org
JP Morgan 2022 – day one sees healthy deal flow from biopharma | Evaluate
Adaptate partners with Iontas
Frontiers | Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
IONTAS and Adaptate Biotherapeutics Collaborate to Identify Optimized Antibodies for Novel Cancer Targets | Lab Manager
Takeda adquiere Adaptate Biotherapeutics para desarrollar nuevas terapias de activación de células T gamma delta dirigidas a tumores sólidos
Andy Chi on LinkedIn: Takeda to Acquire Adaptate Biotherapeutics to Develop Novel GammaDelta…
Tim Haines auf LinkedIn: Takeda to acquire Adaptate Biotherapeutics
Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer - Microbioz India
Adaptate Biotherapeutics raises $18 million in Series A2 funding | Cambridge Network
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors | Business Wire
